SEC61B

Across TCGA pan-cancer cohorts, SEC61B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SEC61B data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SEC61B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SEC61B expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where SEC61B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.494	1.000	.001	68	view →
PDAC	DFS	Median	All	0.206	0.417	.005	14	view →
GBM	DFS	Median	All	0.656	0.770	.011	4	view →
LUAD	DFS	Quartile	All	0.998	0.867	.023	3	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SEC61B–CCRCC (OS)

Open the CCRCC breakdown →